TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04918628
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A humanized anti-PD-1 monoclonal antibody
Study: NCT06134895
Drug: Tramadol with Ketamine
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol with Ketamine is being provided randomly using prospective, double-blind
Study: NCT06134895
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol alone is being provided randomly using prospective, double-blind
Study: NCT04771871
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin is an antitumor antibiotics with good activity on breast cancer. It has less cardiotoxic effect than doxorubicin
Study: NCT04771871
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel is a taxane chemotherapy agent indicated for the treatment of many cancers including breast cancer. It can be used alone or in combination with other drugs
Study: NCT04771871
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is a platinum compound indicated for the treatment of many types of malignancies including breast cancer
Study: NCT05511844
Drug: ORM-5029
Normalized name: ORM-12741
DrugBank: ORM-12741 (DB12057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05529173
Drug: Povidone-Iodine 10%
Normalized name: Povidone-Iodine 10% Topical ointment
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal swab stick application of Povidone-Iodine 10% prior to surgery
Study: NCT04865978
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients randomized to apixaban will be started on a dose of 5 mg BID.
Study: NCT04865978
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to warfarin will be started on a dose per institutional protocol and titrated to an INR goal of 2.0 - 2.5.
Study: NCT06150014
Drug: Entecavir dispersible tablets
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir inhibits viral replication and indicated for chronic hepatitis B treatment.
Study: NCT06150014
Drug: Tenofovir disoproxil fumarate tablet
Normalized name: Tenofovir Disoproxil Fumarate Tablets
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate is a Nucleotide reverse transcriptase inhibitor.
Study: NCT06150014
Drug: Tenofovir alafenamide fumarate tablet
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.
Study: NCT06232421
Drug: Povidon-iodine
Normalized name: Povidone-Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine solution 100 mg/ml produced by BelAseptika CJSC, Republic of Belarus
Study: NCT05013229
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
Study: NCT05013229
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
Study: NCT06054464
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part 1: Daily oral dose of rabeprazole on days 11-14.
Study: NCT06054464
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part 2: Twice daily oral dose of famotidine on days 11-13. Single, oral dose of famotidine on day 14.
Study: NCT06361810
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administer at 400 mg IV every 6 weeks in combination with 177Lu-PNT2002 until the maximum tolerated dose of 177Lu-PNT2002 is reached during the dose escalation phase.~Pembrolizumab will be administer at 400 mg IV every 6 weeks for a maximum of 17 cycles (6 weeks in each cycle) during the dose expansion phase.
Study: NCT06361810
Drug: 177Lu-PNT2002
Normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-PNT2002 given intravenously every 8 weeks will be administered at 3.4 GBq, 6.1 Gbq, or 6.8 Gbq in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks until the maximum tolerated dose is reached during the dose escalation phase.~177Lu-PNT2002 given intravenously every 8 weeks will be administered at the determined maximum tolerated dose for a maximum of 4 cycles in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks for a maximum of 17 cycles.
Study: NCT06361810
Drug: (F-18)-DCFPyL
Normalized name: (18F)DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered 18F-DCFPyL as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.
Study: NCT05995366
Drug: ABBV-903
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution; Oral
Study: NCT04367935
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline tablets 400mg three times daily for 2 months
Study: NCT05800847
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin will be administered for 2 days at 100 mg q8h for titration to avoid side effects. The next 12 days, gabapentin will be taken at 300 mg q8h.
Study: NCT04877639
Drug: Esmketamine,Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two different drugs were given to observe which of the two drugs was more suitable for DISE detection
Study: NCT06254690
Drug: Pyrotinib dose escalation
Normalized name: peanut allergenic extract
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib: 240mg in the first week, 320mg in the second week, and 400mg in the third week and thereafter, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
Study: NCT06254690
Drug: Pyrotinib dose normal
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib: 400mg per week, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
Study: NCT00000446
Drug: sertraline (Zoloft)
Normalized name: sertraline Oral Solution [Zoloft]
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06279403
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative Treatment with Toripalimab: Administer 240mg of Toripalimab via intravenous infusion every 3 weeks for a total of 4 cycles.
Study: NCT06279403
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative Treatment with Axitinib: Administer 5mg of axitinib orally twice daily for a duration of 3 months.
Study: NCT05516966
Drug: Dulaglutide Injection
Normalized name: Dulaglutide Injection
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administrated SC
Study: NCT04928339
Drug: Bupivacaine Injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mL of 0.25% bupivacaine
Study: NCT04928339
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mL of 133mg liposomal bupivacaine
Study: NCT05835687
Drug: B7-H3-CAR T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous T cells transduced with a lentiviral vector expressing a B7-H3-CAR with a CD28z signaling domain and 41BB ligand (B7-H3-CAR T cells). Four (4) infusions of B7-H3-CAR T cells will be locoregionally administered via CNS reservoir catheter.
Study: NCT05861453
Drug: Epeleuton
Normalized name: Epeleuton
DrugBank: Epeleuton (DB18100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2000mg Epeleuton (DS102) capsules twice daily.
Study: NCT06465368
Drug: PF-07220060
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07220060 given as tablet by mouth twice a day for 14 days.
Study: NCT06465368
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole given as tablet by mouth once a day for 14 days
Study: NCT05577715
Drug: MORAb-202
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT04895280
Drug: Marcaine
Normalized name: Marcaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Marcaine (control): will receive an injection of 4 cc 0.25% Marcaine without epinephrine
Study: NCT04895280
Drug: Kenalog
Normalized name: Kenalog
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kenalog: 4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1.
Study: NCT04995003
Drug: Pembrolizumab Injectable Product
Normalized name: pembrolizumab Injectable Product
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 mg/kg/dose (max 200 mg/dose) every 3 weeks
Study: NCT04995003
Drug: Nivolumab Injectable Product
Normalized name: nivolumab Injectable Product
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 mg/kg/dose (\<40kg) or 124 mg (≥40 kg) every 2 weeks
Study: NCT05890586
Drug: Fluvoxamine
Normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days.
Study: NCT05376553
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 350mg intravenous infusion over 30 minutes
Study: NCT05376553
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg/m² intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline~Schedule: Day 1, every 21 days (+ 2 days)
Study: NCT05376553
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/2 intravenous infusion over 60 minutes, mixed as described in~Schedule: Day 1, every 21days (+ 2 days)
Study: NCT05041582
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: total 3 months, since 2-4 weeks after stroke
Study: NCT05364489
Drug: Bevacizumab combined with Oxaliplatin and TAS-102
Normalized name: Oxaliplatin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (Anda, Qilu Pharmaceutical): 5 mg/kg, repeated every 2 weeks, administered by intravenous drip (ivgtt).~Oxaliplatin: 85 mg/m2, repeated every 2 weeks, by intravenous infusion (ivgtt). TAS-102: 35 mg/m2 (maximum single dose 80 mg), orally, twice a day, on days 1 to 5, repeated every 2 weeks.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug .
Study: NCT06106295
Drug: Metyrapone
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 to 1000 milligram (mg) orally in one or two doses in the evening (administered 4 and 2 hours prior to bed)
Study: NCT06131593
Drug: TAPB with dexamethasone as an adjuvant to local anesthetics
Normalized name: Aldex AN
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive TAPB with dexamethasone as an adjuvant to bupivacaine and lidocaine local anesthetics
Study: NCT05863364
Drug: Low-dose of Rifaximin
Normalized name: ethinyl estradiol
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients in group B were given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks
Study: NCT05863364
Drug: Conventional dose of Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the patients in group C were delivered 1200mg/d (600mg, bid) for 24 weeks
Study: NCT06455254
Drug: Candonilimab (AK104)
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab (AK104): 6mg/kg, i.v. q2w.
Study: NCT06455254
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib: 80 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).
Study: NCT04595370
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive dapagliflozin as per the arms they are randomized.
Study: NCT03399773
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03399773
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05034887
Drug: Trastuzumab Deruxtecan (T-DXd) monotherapy
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T-DXd will be administered at a dose of 6.4 mg/kg (decimal) by intravenous infusion every 21 days (3 weeks) for subsequent three cycles.
Study: NCT05261139
Drug: nirmatrelvir
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-07321332
Study: NCT05261139
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ritonavir
Study: NCT05849662
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO or NG QD Days 1-28~For patients age \< 6 years: 0.032 mg/kg/day at max dose = 2mg/day~For patients age ≥ 6 years: 0.025 mg/kg/day at max dose = 2 mg/day
Study: NCT05849662
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV over 30 minutes Days 1-5~Age \< 1 year or weight \<10kg:~2.5 mg/kg/day~Age ≥ 1 year and weight ≥ 10kg:~75 mg/m2/day
Study: NCT05849662
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV over 30 minutes Days 6-10~30 mg/m2/day (1mg/kg if \<12 kg)
Study: NCT05849662
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV over 3 hours Days 6-10~2000 mg/m2/day (67mg/kg if \<12 kg)
Study: NCT06157827
Drug: Etoposide Injection
Normalized name: etoposide Injection
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
Study: NCT06157827
Drug: Carboplatin Injection
Normalized name: Carboplatin Injection
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
Study: NCT06157827
Drug: Atezolizumab injection
Normalized name: atezolizumab Injection
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial dose; Q3W; intravenous infusion
Study: NCT06157827
Drug: Cisplatin injection
Normalized name: cisplatin Injection
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
Study: NCT05704036
Drug: Transdermal estrogen
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 0.1 mg/day, applied once weekly
Study: NCT05704036
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive
Study: NCT06087328
Drug: Regular Nicotine patch and lozenge dose
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg patch, qd + 4mg lozenge prn \[minimum of 5 \& up to 20 per day\]
Study: NCT06087328
Drug: Augmented Nicotine patch and lozenge dose
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21mg patch + 14mg patch qd + 4mg lozenge prn \[minimum of 5 \& up to 30 per day\] OR 2 x 21mg patches qd + 4mg lozenges prn \[minimum of 5 \& up to 40 per day\]
Study: NCT06563349
Drug: Normal saline infusion
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intravenous normal saline infusion.
Study: NCT06462573
Drug: locally infilterating anaethesia like lidocaine
Normalized name: insulin-like growth factor 2
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: which patients will undergo ESWL under locally infiltrated anaesthetic. Using ultrasound guidance, the quadratus lumborum muscle will be identified. Then a mixture of 0.5 % bupivacaine (10 ml) and 2 % lidocaine (10 ml) will be injected into the muscle as a single shot 20 minutes before the procedure.
Study: NCT04933227
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1200 mg will be administered intravenously (IV) on Day 1 of each 21-day cycle.
Study: NCT04933227
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab 600 mg will be administered IV on Day 1 of each 21-day cycle.
Study: NCT04933227
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle during Cycles 1-4.
Study: NCT05852717
Drug: Epcoritamab
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epcoritamab
Study: NCT05195632
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hard capsule
Study: NCT05195632
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Film-coated tablet
Study: NCT05694637
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Referral to treatment with varenicline will be provided to those identified as needing more than a brief intervention. Participants will initiate medication treatment with varenicline for smoking cessation with a quit date scheduled for day 8 following first study dose of the medication. Participants will meet with the study clinician at baseline who will provide medical clearance and sign off on prescription orders. All medication will be provided to participants by the study team. Participants will receive a weekly supply of medication for the first four weeks to ensure proper dosing and monitor for adverse events. For the subsequent 8 weeks, participants will return every 4 weeks to receive the next month's supply of medication. Dosage adjustments will be permitted in an effort to control adverse effects throughout the trial. This will allow us to balance internal validity with good clinical practice. Varenicline will be dosed in accordance with package labeling.
Study: NCT06029998
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sub-cutaneous injection of bortezomib for 6-8 cycles of treatment.
Study: NCT05354258
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthelminthic drugs for the treatment of soil-transmitted helminths
Study: NCT05354258
Drug: Praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthelminthic drugs for the treatment of schistosomiasis
Study: NCT05354258
Drug: Amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SMC partner drug
Study: NCT05354258
Drug: Sulfadoxine pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SMC partner drug
Study: NCT05662943
Drug: Intravitreal aflibercept injection
Normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection of aflibercept (0.2 mg / 0,05 ml; Bayer Co. Ltd.,)
Study: NCT06494514
Drug: nal-IRI+Oxaliplatin+5-FU/LV+PD-1
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: These drugs are given on d1, d15, 28 days as one cycle. 6-6 treatment cycles. SBRT is performed in third cycles.
Study: NCT06494514
Drug: Gemcitabine + albumin-paclitaxel+PD-1
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: These drugs are given on d1, d8, 21 days as one cycle. 6-6 treatment cycles. SBRT is performed in third cycles.
Study: NCT01084486
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no